Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tecovirimat for the Treatment of Human Mpox Virus Disease
NCT05534984Phase 3Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2022
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of tecovirimat in mpox, sponsored by National Institute of Allergy and Infectious Diseases. Started Sep 2022; status: terminated.
02
Drugs
tecovirimat
03
Conditions
mpox
Beyond the preview
Go deeper on NCT05534984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05534984.